Entero Therapeutics (ENTO) Competitors $2.75 +0.45 (+19.74%) As of 10:35 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ENTO vs. LSB, SYBX, AIMD, LEXX, EDSA, CYCC, PULM, IBIO, MTVA, and ATNFShould you be buying Entero Therapeutics stock or one of its competitors? The main competitors of Entero Therapeutics include LakeShore Biopharma (LSB), Synlogic (SYBX), Ainos (AIMD), Lexaria Bioscience (LEXX), Edesa Biotech (EDSA), Cyclacel Pharmaceuticals (CYCC), Pulmatrix (PULM), iBio (IBIO), MetaVia (MTVA), and 180 Life Sciences (ATNF). These companies are all part of the "pharmaceutical products" industry. Entero Therapeutics vs. Its Competitors LakeShore Biopharma Synlogic Ainos Lexaria Bioscience Edesa Biotech Cyclacel Pharmaceuticals Pulmatrix iBio MetaVia 180 Life Sciences LakeShore Biopharma (NASDAQ:LSB) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings. Does the media refer more to LSB or ENTO? In the previous week, LakeShore Biopharma had 2 more articles in the media than Entero Therapeutics. MarketBeat recorded 5 mentions for LakeShore Biopharma and 3 mentions for Entero Therapeutics. Entero Therapeutics' average media sentiment score of 1.22 beat LakeShore Biopharma's score of 0.79 indicating that Entero Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LakeShore Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Entero Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, LSB or ENTO? LakeShore Biopharma has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Entero Therapeutics has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Do insiders and institutionals have more ownership in LSB or ENTO? 52.6% of LakeShore Biopharma shares are held by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has better earnings and valuation, LSB or ENTO? LakeShore Biopharma has higher revenue and earnings than Entero Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLakeShore Biopharma$85.67M0.20-$13.93MN/AN/AEntero TherapeuticsN/AN/A-$18.06MN/AN/A Is LSB or ENTO more profitable? LakeShore Biopharma's return on equity of 0.00% beat Entero Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets LakeShore BiopharmaN/A N/A N/A Entero Therapeutics N/A -1,063.82%-17.94% SummaryLakeShore Biopharma beats Entero Therapeutics on 6 of the 9 factors compared between the two stocks. Get Entero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENTO vs. The Competition Export to ExcelMetricEntero TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.40M$3.18B$5.82B$10.13BDividend YieldN/A2.32%5.69%4.62%P/E RatioN/A21.5074.8626.13Price / SalesN/A297.34467.6691.41Price / CashN/A45.3337.0859.91Price / Book-1.129.6812.096.33Net Income-$18.06M-$53.32M$3.29B$270.76M7 Day Performance2.00%0.87%1.42%3.50%1 Month Performance41.23%9.65%7.70%6.83%1 Year Performance178.18%13.23%62.04%28.21% Entero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENTOEntero TherapeuticsN/A$2.75+19.6%N/A+74.2%$4.40MN/A0.009Positive NewsShort Interest ↓LSBLakeShore Biopharma1.3066 of 5 stars$0.85+3.0%N/A-83.9%$17.57M$85.67M0.00773Short Interest ↓Gap DownSYBXSynlogic1.6725 of 5 stars$1.49+2.1%N/A+6.5%$17.43MN/A-18.6380Positive NewsShort Interest ↓Gap UpAIMDAinos1.0775 of 5 stars$3.74+2.2%N/A+38.8%$17.43M$20K-0.7540LEXXLexaria Bioscience3.9101 of 5 stars$0.89+0.1%$4.00+351.0%-69.9%$17.35M$460K-1.327Short Interest ↓EDSAEdesa Biotech1.4658 of 5 stars$2.45+4.7%$5.00+104.1%-44.9%$17.25MN/A-1.8620CYCCCyclacel Pharmaceuticals0.4561 of 5 stars$7.69flatN/A-97.6%$17.23M$40K-0.0114Short Interest ↑PULMPulmatrix0.9758 of 5 stars$4.65-2.3%N/A+166.1%$16.97M$369K-2.1420Short Interest ↓IBIOiBio1.9536 of 5 stars$0.86+5.9%$5.00+482.2%-49.3%$16.88M$375K0.00100Short Interest ↑MTVAMetaVia2.683 of 5 stars$0.67+5.1%$7.50+1,020.2%N/A$16.20MN/A0.008Positive NewsATNF180 Life Sciences0.211 of 5 stars$2.67-5.0%N/A+40.3%$16.12MN/A-0.187 Related Companies and Tools Related Companies LakeShore Biopharma Competitors Synlogic Competitors Ainos Competitors Lexaria Bioscience Competitors Edesa Biotech Competitors Cyclacel Pharmaceuticals Competitors Pulmatrix Competitors iBio Competitors MetaVia Competitors 180 Life Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENTO) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersNVDA: The cracks are beginning to showThe media hasn't caught up to the story yet, but when they do, this stock could leave Nvidia in the dust. I...InvestorPlace | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENTO Stock Alerts